A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

Cancer

Volumn 91, Issue 1, 2001, Pages 144-154

  Berenson, James R ^a   Vescio, Robert ^b   Henick, Kathryn ^b   Nishikubo, Carol ^b   Rettig, Matthew ^b   Swift, Regina A ^b   Conde, Francisco ^b   Von Teichert, Joseph M ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonate; Bone metastasis; Bone resorption; Deoxypyridinoline; N telopeptide; Osteolytic lesion; Pyridinoline; Zoledronate; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; N ACETYL BETA GLUCOSAMINIDASE; PEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; LEG EDEMA; MALE; MUSCLE DISEASE; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; URINE LEVEL;

ADULT; AGED; ANOREXIA; BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; CONSTIPATION; DIPHOSPHONATES; FEMALE; FEVER; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; TREATMENT OUTCOME;

EID: 0035174823     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q     Document Type: Article

References (60)

1. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
2. Bone destruction and hypercalcemia in plasma cell myeloma
3. Multiple myeloma: A review of 869 cases
4. Mechanisms of osteolytic bone destruction
5. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption
6. Rationale for the use of bisphosphonates in bone metastases
7. Current use of bisphosphonates in oncology
8. Bisphosphonates: Mechanisms of action and clinical use in osteoporosis - An update
9. Bisphosphonates: Preclinical aspects and use in osteoporosis
10. Comparative study of available medical therapy for hypercalcemia of malignancy
11. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia
12. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer
13. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP
14. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
15. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate
16. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate [APD]) as single shot treatment of hypercalcemia
17. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate
18. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusions
19. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
20. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
21. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
22. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
23. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma
24. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
25. Palliative pamidronate treatment in patients with bone metastases from breast cancer
26. Structure-activity relationships of various bisphosphonates
27. Pamidronate
28. Generalized increase in bone resorption in carcinoma of the prostate
29. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption
30. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study
31. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
32. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models
33. A dose-finding study of zoledronate in hypercalcemic cancer patients
34. Clinical research update: Zoledronate
35. Bisphosphonates inhibit breast cancer cell proliferation
36. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
37. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independent of apoptosis induction
38. Bisphosphonates inhibit the platelet-aggregating activity of tumor cells, a process involved during hematogenous dissemination of metastatic cells
39. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion
40. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
41. Markers of bone resorption in patients treated with pamidronate
42. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy
43. Phase I trial of zoledronate (CGP-42446), a new bisphosphonate, in patients with osteolytic bone lesions
44. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
45. Diagnostic validity of bone metabolic markers for bone metastasis
46. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
47. Supportive care and quality of life
48. Assessment of renal function in patients with multiple myeloma: The role of urinary proteins
49. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
50. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
51. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse
52. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice
53. Biochemical markers of bone metabolism: An overview
54. Clinical utility of biochemical markers of bone remodeling
55. Phase II open label, dose ranging, safety trial of rapid intravenous zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone metastases
56. Zoledronic acid is superior to pamidronate in the treatment of tumor-induced hypercalcemia: A pooled analysis
57. Molecular mechanisms of action of bisphosphonates
58. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
59. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo